Hi ratkin. I think your "aimed shotgun" approach to biotech - or, "life sciences" as I'm learning to call them! - may be the way to go. There are similar risks to investing in unproven mining exploration companies, IMO, but always the chance of stumbling on a CSL or a Cochlear!

I'm still interested in Starpharma SPL but havn't bought any yet. I like their strong position in the development of dendrimer products although must admit that I don't fully understand the science. The SP took a hit recently when stage 3 test results on their lead product, VivaGel, weren't as conclusive as hoped but more recently again there was an encouraging test result on their docetaxel cancer drug. Directors have been buying at these lower SP levels which is often a bullish sign.

Have a look at the presentation from the AGM on 30 November, for more details. ( Tried to attach but having PC problems!)